Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka, P, Schlenk, RF, Weber, D, Benner, A, Bullinger, L, Heuser, M, Gaidzik, VI, Thol, F, Agrawal, M, Teleanu, V, Lubbert, M, Fiedler, W, Radsak, M, Krauter, J, Horst, HA, Greil, R, Mayer, K, Kundgen, A, Martens, U, Heil, G, Salih, HR, Hertenstein, B, Schwanen, C, Wulf, G, Lange, E, Pfreundschuh, M, Ringhoffer, M, Girschikofsky, M, Heinicke, T, Kraemer, D, Gohring, G, Ganser, A, Dohner, K, Dohner, H.

http://www.ncbi.nlm.nih.gov/pubmed/29720733